<p>Tenax Therapeutics, Inc.（納斯達克代碼：TENX - 獲取免費報告）內部人士 Stuart Rich 於 12 月 4 日星期四購買了 2,500 股該公司的股票。每股平均購買價格為 9.20 美元，總交易額為 23,000.00 美元。交易完成後，該內部人士直接持有 2,500 股公司股票，價值 23,000 美元。這筆交易代表了他們對該股票的持有量增加了∞。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。</p>
<p>Stuart Rich 最近還進行了以下交易：</p>
<ul>
<li>在 12 月 3 日星期三，Stuart Rich 購買了 1,500 股 Tenax Therapeutics 的股票。股票的平均購買價格為每股 9.08 美元，總價值為 13,620.00 美元。</li>
<li>在 12 月 2 日星期二，Stuart Rich 收購了 1,000 股 Tenax Therapeutics 的股票。每股平均購買價格為 9.01 美元，總交易額為 9,010.00 美元。</li>
</ul>
<p>獲取 <strong>Tenax Therapeutics</strong> 的提醒：</p>
<h2>Tenax Therapeutics 股價上漲 3.2%</h2>
<p>在週五的午盤交易中，TENX 的股價上漲了 0.30 美元，達到了 9.65 美元。該股票的交易量為 168,431 股，而其平均交易量為 50,192 股。該公司的 50 日簡單移動平均線為 7.66 美元，200 日簡單移動平均線為 6.58 美元。該公司的市值為 6025 萬美元，市盈率為-8.54，貝塔值為 1.55。Tenax Therapeutics, Inc.的 52 周最低價為 4.63 美元，52 周最高價為 9.91 美元。</p>
<p>Tenax Therapeutics（納斯達克代碼：TENX - 獲取免費報告）最近一次發佈季度財報是在 11 月 12 日星期三。這家專業製藥公司報告本季度每股收益（EPS）為-0.40 美元，超出分析師一致預期的-1.33 美元，超出幅度為 0.93 美元。分析師平均預計 Tenax Therapeutics, Inc.在當前財政年度的每股收益為-0.88 美元。</p>
<h2>分析師設定新的目標價</h2>
<p>TENX 已成為幾份研究分析報告的主題。Guggenheim 在 8 月 14 日的研究報告中將 Tenax Therapeutics 的目標價從 15.00 美元下調至 14.00 美元，並對該股票給予 “買入” 評級。華爾街 Zen 在 10 月 25 日的報告中將 Tenax Therapeutics 的股票評級上調至 “賣出”。Weiss Ratings 在週一的研究報告中重申了對 Tenax Therapeutics 股票的 “賣出（e+）” 評級。最後，Piper Sandler 在 9 月 8 日的研究報告中開始覆蓋 Tenax Therapeutics 的股票，給予 “增持” 評級，並設定 20.00 美元的目標價。三位分析師對該股票給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 18.00 美元。</p>
<p><strong>獲取我們關於 TENX 的最新股票報告</strong></p>
<h2>機構投資者對 Tenax Therapeutics 的看法</h2>
<p>機構投資者和對沖基金最近增加或減少了對該股票的持倉。Virtu Financial LLC 在第三季度購買了 Tenax Therapeutics 的新股份，價值約 92,000 美元。Citadel Advisors LLC 在第三季度將其在 Tenax Therapeutics 的持股增加了 318.1%。Citadel Advisors LLC 現在擁有 43,253 股這家專業製藥公司的股票，價值 329,000 美元，此前在上個季度又購買了 32,908 股。ADAR1 Capital Management LLC 在第一季度將其在 Tenax Therapeutics 的持股增加了 98.1%。ADAR1 Capital Management LLC 現在擁有 68,741 股這家專業製藥公司的股票，價值 450,000 美元，此前又購買了 34,048 股。Woodline Partners LP 在第三季度收購了 Tenax Therapeutics 的新股份，價值約 671,000 美元。最後，Millennium Management LLC 在第三季度將其在 Tenax Therapeutics 的持股增加了 34.2%。Millennium Management LLC 現在擁有 313,712 股這家專業製藥公司的股票，價值 2,387,000 美元，此前在上個季度又收購了 79,998 股。目前，1.67% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Tenax Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Tenax Therapeutics, Inc.開發和商業化含有伊馬替尼的藥物產品，用於治療美國的肺動脈高壓。該公司開發的 TNX-101（IV）、TNX-102 和 TNX-103（左西孟旦）已完成針對與心力衰竭伴有保留射血分數相關的肺動脈高壓患者的二期臨牀試驗；以及 TNX-201（伊馬替尼），一種用於治療慢性髓性白血病的酪氨酸激酶抑制劑。</p>
<h2>精選故事</h2>
<ul>
<li>我們更喜歡的五隻股票超過 Tenax Therapeutics</li>
<li>使用 MarketBeat 股息税計算器</li>
<li>Rocket Lab 的大反彈？分析師認為下跌是一個機會</li>
<li>製造業股票投資</li>
<li>Meta 的人工智能時刻？新的 SAM 3 模型讓華爾街變得樂觀</li>
<li>這些液化天然氣股票準備迎來反彈嗎？</li>
<li>Snowflake 股票：聰明投資者正在購買的下跌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVOWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Tenax Therapeutics 嗎？</h2>
<p>在考慮 Tenax Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tenax Therapeutics 並不在名單上。</p>
<p>雖然 Tenax Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TENX

<p>Tenax Therapeutics 的內部人士 Stuart Rich 以每股 9.20 美元的價格購買了 2,500 股，總計 23,000 美元。此交易已向 SEC 披露，顯著增加了他的持股比例。最近的交易包括以 9.08 美元購買 1,500 股和以 9.01 美元購買 1,000 股。TENX 股價上漲 3.2% 至 9.65 美元。分析師的評級不一，普遍目標價為 18.00 美元。機構投資者已調整其持股比例，Citadel Advisors 和 Millennium Management 的增持尤為顯著</p>

<p>Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) insider Stuart Rich bought 2,500 shares of the business's stock in a transaction dated Thursday, December 4th. The shares were bought at an average cost of $9.20 per share, for a total transaction of $23,000.00. Following the completion of the transaction, the insider directly owned 2,500 shares of the company's stock, valued at $23,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.</p>
<div class="lb-trans"><p>Tenax Therapeutics, Inc.（納斯達克代碼：TENX - 獲取免費報告）內部人士 Stuart Rich 於 12 月 4 日星期四購買了 2,500 股該公司的股票。每股平均購買價格為 9.20 美元，總交易額為 23,000.00 美元。交易完成後，該內部人士直接持有 2,500 股公司股票，價值 23,000 美元。這筆交易代表了他們對該股票的持有量增加了∞。該交易已在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。</p>
</div><p>Stuart Rich also recently made the following trade(s):</p>
<div class="lb-trans"><p>Stuart Rich 最近還進行了以下交易：</p>
</div><ul>
<li>On Wednesday, December 3rd, Stuart Rich purchased 1,500 shares of Tenax Therapeutics stock. The stock was bought at an average price of $9.08 per share, with a total value of $13,620.00.</li>
<li>On Tuesday, December 2nd, Stuart Rich acquired 1,000 shares of Tenax Therapeutics stock. The shares were bought at an average price of $9.01 per share, for a total transaction of $9,010.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 3 日星期三，Stuart Rich 購買了 1,500 股 Tenax Therapeutics 的股票。股票的平均購買價格為每股 9.08 美元，總價值為 13,620.00 美元。</li>
<li>在 12 月 2 日星期二，Stuart Rich 收購了 1,000 股 Tenax Therapeutics 的股票。每股平均購買價格為 9.01 美元，總交易額為 9,010.00 美元。</li>
</ul>
</div><p>Get <strong>Tenax Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tenax Therapeutics</strong> 的提醒：</p>
</div><h2>Tenax Therapeutics Trading Up 3.2%</h2>
<div class="lb-trans"><h2>Tenax Therapeutics 股價上漲 3.2%</h2>
</div><p>Shares of TENX traded up $0.30 during midday trading on Friday, hitting $9.65. The stock had a trading volume of 168,431 shares, compared to its average volume of 50,192. The business has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $6.58. The firm has a market cap of $60.25 million, a P/E ratio of -8.54 and a beta of 1.55. Tenax Therapeutics, Inc. has a fifty-two week low of $4.63 and a fifty-two week high of $9.91.</p>
<div class="lb-trans"><p>在週五的午盤交易中，TENX 的股價上漲了 0.30 美元，達到了 9.65 美元。該股票的交易量為 168,431 股，而其平均交易量為 50,192 股。該公司的 50 日簡單移動平均線為 7.66 美元，200 日簡單移動平均線為 6.58 美元。該公司的市值為 6025 萬美元，市盈率為-8.54，貝塔值為 1.55。Tenax Therapeutics, Inc.的 52 周最低價為 4.63 美元，52 周最高價為 9.91 美元。</p>
</div><p>Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($1.33) by $0.93. On average, analysts expect that Tenax Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Tenax Therapeutics（納斯達克代碼：TENX - 獲取免費報告）最近一次發佈季度財報是在 11 月 12 日星期三。這家專業製藥公司報告本季度每股收益（EPS）為-0.40 美元，超出分析師一致預期的-1.33 美元，超出幅度為 0.93 美元。分析師平均預計 Tenax Therapeutics, Inc.在當前財政年度的每股收益為-0.88 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的目標價</h2>
</div><p>TENX has been the topic of several research analyst reports. Guggenheim lowered their target price on Tenax Therapeutics from $15.00 to $14.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Tenax Therapeutics to a &#34;sell&#34; rating in a report on Saturday, October 25th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Tenax Therapeutics in a research note on Monday. Finally, Piper Sandler began coverage on shares of Tenax Therapeutics in a research report on Monday, September 8th. They issued an &#34;overweight&#34; rating and a $20.00 target price for the company. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $18.00.</p>
<div class="lb-trans"><p>TENX 已成為幾份研究分析報告的主題。Guggenheim 在 8 月 14 日的研究報告中將 Tenax Therapeutics 的目標價從 15.00 美元下調至 14.00 美元，並對該股票給予 “買入” 評級。華爾街 Zen 在 10 月 25 日的報告中將 Tenax Therapeutics 的股票評級上調至 “賣出”。Weiss Ratings 在週一的研究報告中重申了對 Tenax Therapeutics 股票的 “賣出（e+）” 評級。最後，Piper Sandler 在 9 月 8 日的研究報告中開始覆蓋 Tenax Therapeutics 的股票，給予 “增持” 評級，並設定 20.00 美元的目標價。三位分析師對該股票給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 18.00 美元。</p>
</div><p><strong>Get Our Latest Stock Report on TENX</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 TENX 的最新股票報告</strong></p>
</div><h2>Institutional Investors Weigh In On Tenax Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Tenax Therapeutics 的看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in Tenax Therapeutics during the third quarter valued at about $92,000. Citadel Advisors LLC raised its stake in Tenax Therapeutics by 318.1% during the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company's stock valued at $329,000 after purchasing an additional 32,908 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in shares of Tenax Therapeutics by 98.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company's stock worth $450,000 after purchasing an additional 34,048 shares during the period. Woodline Partners LP acquired a new stake in Tenax Therapeutics during the third quarter worth about $671,000. Finally, Millennium Management LLC raised its holdings in Tenax Therapeutics by 34.2% in the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company's stock valued at $2,387,000 after acquiring an additional 79,998 shares in the last quarter. 1.67% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近增加或減少了對該股票的持倉。Virtu Financial LLC 在第三季度購買了 Tenax Therapeutics 的新股份，價值約 92,000 美元。Citadel Advisors LLC 在第三季度將其在 Tenax Therapeutics 的持股增加了 318.1%。Citadel Advisors LLC 現在擁有 43,253 股這家專業製藥公司的股票，價值 329,000 美元，此前在上個季度又購買了 32,908 股。ADAR1 Capital Management LLC 在第一季度將其在 Tenax Therapeutics 的持股增加了 98.1%。ADAR1 Capital Management LLC 現在擁有 68,741 股這家專業製藥公司的股票，價值 450,000 美元，此前又購買了 34,048 股。Woodline Partners LP 在第三季度收購了 Tenax Therapeutics 的新股份，價值約 671,000 美元。最後，Millennium Management LLC 在第三季度將其在 Tenax Therapeutics 的持股增加了 34.2%。Millennium Management LLC 現在擁有 313,712 股這家專業製藥公司的股票，價值 2,387,000 美元，此前在上個季度又收購了 79,998 股。目前，1.67% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Tenax Therapeutics</h2>
<div class="lb-trans"><h2>關於 Tenax Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.</p>
<div class="lb-trans"><p>Tenax Therapeutics, Inc.開發和商業化含有伊馬替尼的藥物產品，用於治療美國的肺動脈高壓。該公司開發的 TNX-101（IV）、TNX-102 和 TNX-103（左西孟旦）已完成針對與心力衰竭伴有保留射血分數相關的肺動脈高壓患者的二期臨牀試驗；以及 TNX-201（伊馬替尼），一種用於治療慢性髓性白血病的酪氨酸激酶抑制劑。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Tenax Therapeutics</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>Manufacturing Stocks Investing</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票超過 Tenax Therapeutics</li>
<li>使用 MarketBeat 股息税計算器</li>
<li>Rocket Lab 的大反彈？分析師認為下跌是一個機會</li>
<li>製造業股票投資</li>
<li>Meta 的人工智能時刻？新的 SAM 3 模型讓華爾街變得樂觀</li>
<li>這些液化天然氣股票準備迎來反彈嗎？</li>
<li>Snowflake 股票：聰明投資者正在購買的下跌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVOWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=TENX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tenax Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tenax Therapeutics 嗎？</h2>
</div><p>Before you consider Tenax Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tenax Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenax Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tenax Therapeutics 並不在名單上。</p>
</div><p>While Tenax Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tenax Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Tenax Therapeutics (NASDAQ:TENX) 的內部人士 Stuart Rich 購買了 2,500 股股票